Dopamine agonist and tamoxifen combination therapy for a prolactin-secreting pituitary tumor resistant to dopamine agonist monotherapy: Case report and review
Background: The majority of prolactin-secreting pituitary macroadenomas are effectively managed with dopamine-agonist therapy alone. Although surgical resection and radiotherapy are second- and third-line treatment options, there remains a paucity of therapies for when these options fail. Case descr...
Main Authors: | Zachary K. Christian, Kimmo J. Hatanpaa, Richard J. Auchus, Stephen R. Hammes, Ankur R. Patel, Bruce E. Mickey |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-09-01
|
Series: | Interdisciplinary Neurosurgery |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2214751920301584 |
Similar Items
-
Dopamine Agonists for Pituitary Adenomas
by: Odelia Cooper, et al.
Published: (2018-08-01) -
Metabolic effects of prolactin and the role of dopamine agonists: A review
by: Polly Kirsch, et al.
Published: (2022-09-01) -
Dopamine agonist monotherapy utilization in patients with Parkinson’s disease
by: Monica Frazer, et al.
Published: (2023-01-01) -
The effect of dopamine agonist therapy on large functionless pituitary tumours.
by: Grossman, A, et al.
Published: (1985) -
Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms
by: Claudia Pivonello, et al.
Published: (2022-01-01)